Nice try EPITANMAN but as the announcement shows there are some major hurdles ahead for EPT including getting their one big hope "Melanotan" to market. And if successful, possibly having to contend with copy products.
I like the product (Melonotan) and I think it probably will eventually get to market in one form or another. But the issues raised about expiring patents starting and potential problems with regulatory approval are major concerns.
Add to that the limited income forecast for the next 4 to 5 years and you'd have to think there were better short to mid-term investment prospects than EPT.
I actually hold EPT but I wouldn't recommend them, even at these prices.
Nice try EPITANMAN but as the announcement shows there are some...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.62 |
Change
0.390(2.56%) |
Mkt cap ! $761.5M | |||
| Open | High | Low | Value | Volume |
| $15.45 | $15.69 | $15.18 | $368.5K | 23.74K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12 | $15.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.64 | 123 | 5 |
View Market Depth
| Last trade - 13.03pm 25/06/2024 (20 minute delay) ? |
| CUV (ASX) Chart |